CN1977044A - 治疗胰腺癌的组合物和方法 - Google Patents

治疗胰腺癌的组合物和方法 Download PDF

Info

Publication number
CN1977044A
CN1977044A CNA2005800166735A CN200580016673A CN1977044A CN 1977044 A CN1977044 A CN 1977044A CN A2005800166735 A CNA2005800166735 A CN A2005800166735A CN 200580016673 A CN200580016673 A CN 200580016673A CN 1977044 A CN1977044 A CN 1977044A
Authority
CN
China
Prior art keywords
leu
val
gly
ser
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800166735A
Other languages
English (en)
Chinese (zh)
Inventor
中村佑辅
中川英刀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN1977044A publication Critical patent/CN1977044A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800166735A 2004-03-24 2005-03-18 治疗胰腺癌的组合物和方法 Pending CN1977044A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55580904P 2004-03-24 2004-03-24
US60/555,809 2004-03-24

Publications (1)

Publication Number Publication Date
CN1977044A true CN1977044A (zh) 2007-06-06

Family

ID=34961863

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800166735A Pending CN1977044A (zh) 2004-03-24 2005-03-18 治疗胰腺癌的组合物和方法

Country Status (4)

Country Link
EP (1) EP1735442A2 (enExample)
JP (1) JP2007530431A (enExample)
CN (1) CN1977044A (enExample)
WO (1) WO2005090572A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101825799A (zh) * 2010-05-26 2010-09-08 福州华映视讯有限公司 裸眼立体显示器的组立方法
CN104356225A (zh) * 2007-08-20 2015-02-18 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
CN108866058A (zh) * 2018-07-12 2018-11-23 苏州吉玛基因股份有限公司 靶向KRAS的siRNA及其在制备胰腺癌治疗药物中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
WO2010001585A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
DK2519542T3 (en) 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
HRP20180293T1 (hr) 2010-02-10 2018-03-23 Fujifilm Ri Pharma Co., Ltd. Anti-kadherin antitijelo obilježeno radioaktivnim metalom
CN108064244B (zh) 2014-11-14 2021-09-17 诺华股份有限公司 抗体药物缀合物
IL261014B2 (en) * 2016-03-01 2023-10-01 Univ Florida Aav vectors for treatment of dominant retinitis pigmentosa
JP7563694B2 (ja) 2018-06-01 2024-10-08 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 優性網膜色素変性症の処置のための組成物および方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104356225A (zh) * 2007-08-20 2015-02-18 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
CN104356225B (zh) * 2007-08-20 2018-02-13 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
CN101825799A (zh) * 2010-05-26 2010-09-08 福州华映视讯有限公司 裸眼立体显示器的组立方法
CN108866058A (zh) * 2018-07-12 2018-11-23 苏州吉玛基因股份有限公司 靶向KRAS的siRNA及其在制备胰腺癌治疗药物中的应用
CN108866058B (zh) * 2018-07-12 2021-09-10 苏州吉玛基因股份有限公司 靶向KRAS的siRNA及其在制备胰腺癌治疗药物中的应用

Also Published As

Publication number Publication date
WO2005090572A3 (en) 2006-04-13
JP2007530431A (ja) 2007-11-01
EP1735442A2 (en) 2006-12-27
WO2005090572A2 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
CN1922332A (zh) 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
CN1890382A (zh) 检测、诊断和治疗肝细胞癌(hcc)的方法
CN1675359A (zh) 其它新形式的干扰rna分子
CN1656222A (zh) 反义iap核碱基寡聚物及其应用
CN101052644A (zh) 治疗眼新生血管化疾病的RNAi治疗药物
CN1836042A (zh) 用于基因沉默的hbv和hcv保守序列
CN1617929A (zh) siRNA表达系统和利用该系统制备功能性基因击倒细胞的方法
JP2011078418A (ja) 肺癌を治療するための組成物および方法
CN1977044A (zh) 治疗胰腺癌的组合物和方法
Nie et al. Zfp422 promotes skeletal muscle differentiation by regulating EphA7 to induce appropriate myoblast apoptosis
CN1703229A (zh) 治疗前列腺和其他癌的组合物和方法
Maetzig et al. All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase
CN1665930A (zh) 具有RNAi效应的茎环RNA分子的表达系统
CN1904900A (zh) 人类的内源性siRNA序列及其应用和筛选方法
CN1276083C (zh) 用体内产生的ssDNA改变基因表达
JP4467559B2 (ja) 細胞増殖を阻害する組成物および方法
CN1701077A (zh) 反义寡核苷酸用于抑制Akt－1表达的用途
TW200538739A (en) EphA4 as therapeutic target of PRC and PDACa
CN1809583A (zh) 抑制hif－1表达的反义寡核苷酸
CN1882698A (zh) 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
CN1719973A (zh) 用于癌症诊断和治疗的组合物和方法
CA2594245A1 (en) Retrotransposon inhibition in therapy
CN1295331C (zh) 新的癌基因、从其衍生的重组蛋白及其应用
CN101068935A (zh) 与乳腺癌相关的基因和多肽
CN1780913A (zh) 哺乳动物细胞中dsRNA诱导CpG序列甲基化

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication